CCI Merger Clearance for Pharmaceutical Sector Consolidation
CCI merger notification for an acquisition in the pharmaceutical distribution sector — strategic market definition analysis, voluntary remedies design, and advocacy resulting in unconditional Phase 1 clearance.
Practice Areas Involved
The Challenge
A multinational pharmaceutical company sought CCI clearance for its acquisition of a mid-sized Indian pharmaceutical distributor with significant market presence in hospital supply chains across Delhi NCR and four other states. The transaction had a meaningful horizontal overlap in one specialised drug category (oncology distribution) where the combined market share in Delhi NCR would exceed 30% under a narrow market definition. The parties were under significant timeline pressure — the global deal was signed and required CCI clearance within 90 days of the filing date. A Phase 2 investigation would have blown the deadline.
Our Approach
The core strategic question was market definition — the difference between a clean Phase 1 clearance and a Phase 2 investigation depended on whether CCI adopted a narrow (oncology distribution in Delhi NCR) or broad (pharmaceutical distribution nationally) market definition. We led an internal analysis combining distribution channel data, substitutability evidence, and geographic market analysis to develop a robust argument for the broader market definition.
Rather than filing and waiting for CCI's own analysis, we proactively designed a set of voluntary behavioural remedies for the oncology distribution overlap — including supply commitments to alternative distributors for a defined period — and included these in the Form II filing. The voluntary remedy design anticipated the narrow-market concern without conceding that the narrow market definition was correct. This approach — filing remedies alongside the notification rather than in response to a Phase 2 notice — is consistently effective with CCI in transactions with identifiable but manageable concerns.
The Result
CCI granted unconditional Phase 1 clearance in 29 working days — well within the global transaction deadline. The clearance order adopted the broader national market definition, rendering the voluntary remedies unnecessary, but their inclusion in the filing had demonstrably accelerated the review process by removing the CCI team's need to investigate the concern further. The global transaction completed on schedule.
Key Lessons
- ◆Market definition strategy must be developed before filing — post-filing arguments are less persuasive than a proactively developed framework submitted with the notification.
- ◆Voluntary remedies filed alongside the Form II notification — rather than in response to a Phase 2 notice — consistently accelerate CCI review timelines.
- ◆Including voluntary remedies does not constitute an admission that a competition concern exists — they can be designed as a conditional safeguard pending the Commission's own market assessment.
- ◆For global transactions, CCI timeline management should begin at the term sheet stage — not after signing.
Facing a similar challenge?
Our Competition Law team has extensive experience with matters like this. Every consultation is with a senior partner.